Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336340 | 0.93 | ALDH1A1 (0.44) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL334939 | 0.93 | ACHE (0.44) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL7026133 | 0.92 | ALDH1A1 (0.46) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL3110871 | 0.90 | CYP2D6 (0.41) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL766879 | 0.89 | CA12 (0.41) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL13068833 | 0.89 | HTR6 (0.48) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL13025640 | 0.89 | ESR1 (0.42) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL9674450 | 0.88 | CYP2D6 (0.56) | CYP2D6CYP1A2ALDH1A1KMT2AACHE | |
| SCHEMBL11848457 | 0.87 | ESR1 (0.43) | CYP2D6CYP1A2CA12CA1CA9 | |
| SCHEMBL7067476 | 0.87 | ALDH1A1 (0.40) | CYP2D6CYP1A2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4562019-A1 | IP5 SUBSTITUTED COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024023360-A1 | IP5 SUBSTITUTED COMPOUNDS | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284809-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2023-12-06 | — | — | EP | disclosed |
| CN-112574175-B | Quinoline compound, preparation method and application thereof | 南京长澳医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116745304-A | IP4-4,6 substituted derivative compounds | 萨尼菲特治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
| WO-2006086447-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| CN-1756746-A | 6-substituted nicotinamide derivatives as opioid receptor antagonists | LILLY CO ELI (US) | 2006-04-05 | — | — | CN | disclosed |
| WO-2006034446-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034312-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF STEAROYL-COA-DESATURASE (SCD) | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | CYP2D6 793/4885CYP1A2 749/4885CA12 4883/4885 |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | CYP2D6 1766/4885CYP1A2 2236/4885CA12 1840/4885 |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | CYP2D6 25/4885CYP1A2 168/4885CA12 2785/4885 |
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | CYP2D6 62/4885CYP1A2 143/4885CA12 4282/4885 |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, C3AR1 | CYP2D6 785/4885CYP1A2 636/4885CA12 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.